Stanley Druckenmiller's Q1 2026 13F filing reveals NTRA expanded to 18.1% ($613M) of the portfolio, retaining its top holding status, while YPF surged 433% quarter-over-quarter to $150M. Meanwhile, he executed a sweeping rebalancing, fully exiting major positions including XLF ($301M), GOOGL ($121M), and RSP ($225M). Duquesne Family Office's total AUM stands at $2.5B, with 20 holdings this quarter.
Top 5 Holdings — Q1 2026
- NTRA: $613M (18.1%)
- INSM: $189M (5.6%)
- TSM: $167M (5.0%)
- EWZ: $162M (4.8%)
- RSP: $158M (4.7%)
Q1 2026 Key Portfolio Moves
The most striking shift in this filing is a deepening concentration in healthcare. Top holding NTRA (Natera) was increased by an additional 22%, reaching $613M. When combined with INSM ($189M, 5.6%) and Newamsterdam Pharma ($98M, 2.9%), the biotech and healthcare sector accounts for a substantial portion of the portfolio. The newly initiated position in RVMD ($31M) fits the same narrative — a clear signal that Druckenmiller is making concentrated bets on biotechs with active clinical momentum.
- NTRA: Increased +22% to $613M — 18.1% of portfolio; primary biotech conviction bet maintained
- YPF: Increased +433% to $150M — reflects Argentina energy recovery thesis; aggressive EM concentration
- XLF: Fully exited $301M → 0 — complete removal of financials sector exposure; sector rotation signal
- GOOGL: Fully exited $121M → 0 — big tech position liquidated; confirms reduced growth equity stance
- RSP: New position $158M — S&P 500 equal-weight ETF initiated as portfolio diversification hedge
- ARGT: New position $36M — forms concentrated Argentina theme alongside YPF
The expansion of emerging market exposure is equally noteworthy. Brazil ETF EWZ, across two combined positions, approaches $294M, while Argentine state energy company YPF surged 433% to $150M. Argentina ETF ARGT ($36M) was also newly initiated. On the other side, MELI (-94%) and AMZN (-94%) were reduced to near-zero levels, and financials ETF XLF ($301M) along with big tech name GOOGL ($121M) were fully liquidated. This is best interpreted as a strategic pivot — rotating out of growth equities and financials, and shifting the portfolio's center of gravity toward emerging market resources, energy, and biotech.
Tilting Toward EM & Biotech — What's Druckenmiller's Next Move?
Druckenmiller's Q1 2026 portfolio reflects a dual structure of defensive diversification and high-conviction concentrated bets. The overweight in biotech (NTRA, INSM, RVMD) alongside a heavy tilt toward Argentina and Brazil signals a high-risk-tolerance posture. At the same time, the decisive liquidation of large positions in XLF and GOOGL suggests wariness toward current U.S. financials and big tech valuations. The new RSP position reads as a counterbalance to sector concentration risk. Going forward, NTRA's clinical data readouts and shifts in Argentina's macro environment will be the key variables determining whether this portfolio thesis pays off.
